NX

Nexus AGXETRA Nexus Stock Report

Last reporting period 30 Jun, 2024

Updated 06 Nov, 2024

Last price

Market cap $B

1.025

Small

Exchange

XETR - Xetra

NXU.DE Stock Analysis

NX

Neutral

Based on Eyestock quantitative analysis, NXU.DE`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

97/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

4.8 %

Undervalued

Market cap $B

1.025

Dividend yield

0.74 %

Shares outstanding

17.229 B

NEXUS AG is engaged in the development and sale of software and hardware solutions. The company is headquartered in Donaueschingen, Baden-Wuerttemberg and currently employs 1,551 full-time employees. The company went IPO on 2000-07-24. Among others, the Company provides Nexus/HIS, an information system that supports the administrative and medical/nursing areas in hospitals; Nexus/Obstetrics, a documentation software for pregnancies; is also focusing on digital pathology which controls the processes from material entry to billing; Nexus/Psychiatry, a solution for psychiatric institutions from treating patients to key figure management for institution management; CWD - Clinic WindData (E&L), a diagnostics software for the areas of endoscopy, cardiology, sonography and ophthalmology; Nexus/Home, an information system that features finance, resident and treatment management, as well as staff deployment, and Nexus/Curator, a Web-based knowledge database for quality management with document management in health care. The firm operates through subsidiaries in Austria, France, Spain, Switzerland, the Netherlands and Poland, among others.

View Section: Eyestock Rating